Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines
Eli Lilly and Co LLY
$1,183.46
▲ +0.13%
(+$1.57)
Index member:
S&P 500
Open
$1,185.32
Prev Close
$1,181.89
Day Range
$1,160.84 – $1,190.00
52W Range
$712.05 – $1,292.65
Market Cap
$1.08T
P/E (TTM)
41.49
Beta
0.43
Div Yield
0.75%
EPS (TTM)
$29.80
📋 Company Profile
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Country | US |
| Exchange | NEW YORK STOCK EXCHANGE, INC. |
| Currency | USD |
| IPO Date | 1970-07-09 |
| Shares Out. | 941,740,000 |
| Website | lilly.com/ ↗ |
| Phone | 13172762000 |
| Employees | 50,000 |
| Revenue | $22.97B |
| Gross Profit | $19.71B |
| Net Income | $7.10B |
| Free Cash Flow | $18.19B |
| Total Assets | $142.28B |
| Total Liabilities | $108.40B |
| Equity | $33.88B |
About Eli Lilly and Co
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Eli Lilly and Co is a publicly traded company under the ticker symbol LLY on the NEW YORK STOCK EXCHANGE, INC., operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
38 analysts (2026-09-01)
📰 Latest News for LLY
FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
Sector Update: Healthcare Stocks Higher Late Afternoon
How to make sense of 7% mortgage rates and Oracle's AI data center disruption
Sector Update: Healthcare Stocks Edge Higher in Afternoon Trading
Is LLY Stock Cheaper Than It Looks?
Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money?
This week in charts: Novo’s rise and fall and AI biotechs’ big haul

